Published in Hematology Week, June 6th, 2005
Beckloff Associates Inc., a division of Cardinal Health, was chosen by Sanguine as its contract researcher to conduct U.S. Food and Drug Administration (FDA) testing programs for PHER-O2.
The current endeavor includes developing testing projects for a select few indications using the oxygen-carrying attribute of PHER-O2. The analysis is expected to result in selecting a single indication and subsequent testing protocol.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week